Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
Original Maker Recalls Nizatidine over Carcinogen Risks
Zeria Pharmaceutical said on December 3 that it has launched a Class I voluntary recall for some lots of Acinon (nizatidine), which has a similar chemical structure to recall-hit ranitidine, after detecting the cancer-causing contaminant N-nitrosodimethylamine (NDMA). Zeria, which markets…
To read the full story
Related Article
- Yoshindo Recalls Some Nizatidine Products over Carcinogen Risks
October 26, 2023
- Zeria’s Acinon Now Sole Nizatidine Product Being Shipped as Yoshindo Launches Recall
January 13, 2023
- All Ranitidine Tablet Drugs to Be Discontinued in Japan over Carcinogen Woes
July 5, 2021
- Drug Makers Moving to Discontinue Ranitidine/Nizatidine Products over Carcinogen Issue
February 4, 2021
- Carcinogen in On-Market Nizatidine Products Acceptable Levels: MHLW
April 6, 2020
- ICH’s Guidelines Helped Bring NDMA Contamination Problem to Light: NIHS Officials
January 24, 2020
- Ohara Launches Class I Recall for Nizatidine over Carcinogen Risks
October 24, 2019
- GSK Japan to Pull Prescribed Zantac and Compensate for Substitutes; Generic Peers Follow
October 11, 2019
- GSK Japan Ups Recall Level for Zantac to “Class I”
October 10, 2019
- All 11 Manufacturers Pull Ranitidine from Shelves, “Class I” Recalls for 9 Firms
October 4, 2019
- GSK Recalls Zantac as Preventive Measure for NDMA Carcinogenic Risk
September 30, 2019
- MHLW Asks 15 Makers to Investigate Ranitidine, Nizatidine for Potential Carcinogen Contamination
September 20, 2019
BUSINESS
- Pfizer to Donate RSV Jabs to 12 Municipalities in Noto Peninsula
April 22, 2025
- Ono Links Arms with Jorna on RNA Editing Therapeutics
April 22, 2025
- Novo Partners with Asahikawa City on Obesity Measures
April 22, 2025
- Enhertu Hits Mark in 1st Line Breast Cancer with PIII Trial Win
April 22, 2025
- Effexor Filed for Generalized Anxiety Disorder in Japan: Viatris
April 22, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…